Pfizer Calls for Compromise on Retroactively Using Suffixes in Biologic Names

In response to the US Food and Drug Administration’s (FDA) proposal to not go back and rename certain biologics with nonsense suffixes, as it once said it would, Pfizer is calling on the agency to at least retroactively apply suffixes to biologics that serve as reference products for biosimilars.